# Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma

> **NCT06831136** · PHASE2 · RECRUITING · sponsor: **The University of Texas Health Science Center, Houston** · enrollment: 24 (estimated)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** Neoadjuvant Chemotherapy (NAC)
- **DRUG:** Immunotherapy (pembrolizumab)
- **DEVICE:** Endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA)

## Key facts

- **NCT ID:** NCT06831136
- **Lead sponsor:** The University of Texas Health Science Center, Houston
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-26
- **Primary completion:** 2028-01-20
- **Final completion:** 2030-01-20
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06831136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06831136, "Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06831136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*